Weight Loss and Obesity Management Market to attain a valuation of US$ 4.99 Billion by 2028.

The growth of weight loss and obesity management market is attributed to the rising epidemic of obesity across the globe. According to the latest research by Future Market Insights (FMI), the global weight loss and obesity management market is anticipated to reach a valuation of over US$ 4.9 Bn, by the end of 2028. The weight loss and obesity management market is expected to expand at a steady CAGR of 5.2%, over the forecast period of 2018-2028.

Developing Regions More Prone to Obesity & Other Comorbidities

Increasing number of cases of obesity and related comorbidities will lead to the growing adoption of drugs and devices for weight loss and obesity management, which will further fuel the growth of the global weight loss and obesity management market during the forecast period.

The weight loss and obesity management market is majorly driven by the rising prevalence of obesity. The rising epidemic of obesity presents a major challenge to disease prevention across the globe. It is estimated that by 2030, 38% of the world’s adult population will be overweight and around 20% will be obese. This obesity epidemic is more prevalent in the Middle East and the Asia Pacific regions where food import is quite high. Weight loss and obesity management are helpful in the treatment of highly critical obesity and comorbidities associated with it, such as diabetes, asthma, sleep apnea, and hypertension, etc.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-411

Increasing health consciousness is also cited as an important factor boosting the revenue growth of the global weight loss and obesity management market. Sizeable consumer population in developed regional markets will particularly continue to generate high demand for weight loss and obesity management practices, according to the report. Millennial and Generation-X consumers are gradually adopting advanced aesthetic services, including weight loss and obesity management, thereby creating adequate opportunities for manufacturers of weight loss and obesity management drugs and devices.

Key Players:

  • Novo Nordisk A/S,
  • GlaxoSmithKline plc.,
  • F. Hoffmann-La Roche AG,
  • Allergan Plc,
  • Johnson & Johnson Services, Inc,
  • Medtronic plc.,
  • Vivus Inc.,
  • Eisai Co., Ltd.,
  • ReShape Lifesciences, Inc,
  • Obalon Therapeutics,
  • Aspire Bariatrics,
  • Allurion Technologies Inc.,
  • Nalpropion Pharmaceuticals, Inc., and
  • Beijing Noble Laser Technology Co., Ltd.

Key Vendors Targeting Extension of Product Portfolio

Leading companies operating in weight loss and obesity management market are majorly focusing on strengthening their product portfolio. Product line extensions help companies to launch newer products with unique features for specific indications. This results in an increased market share of companies in the highly competitive weight loss and obesity management market. In response to increasing demand from various healthcare professionals to effectively treat obesity with minimum long-term side effects, manufacturers are focusing on developing innovative and specific products.

Product innovation is expected to boost revenue and volume growth of the weight loss and obesity management market during the forecast period. For instance, an additional FDA patents approval for VIVUS, Inc.’s Qsymia, for the covering compositions of Qsymia and covering methods for effecting weight loss using Qsymia (phentermine and topiramate).

However, the high cost involved in research and development of obesity drugs is a great challenge for the growth of the weight loss and obesity management market. Additionally, long gestation time required for research and developmental activities as well as the need for a number of essential clinical trials to test drugs adds up to significant expenditure. The limitations posed by high development cost of anti-obesity drugs might hinder the growth of the global weight loss and obesity management market. Moreover, the high cost of surgical procedures, such as gastric bypass surgery, adjustable gastric banding, gastric sleeve surgery and gastric balloon treatment, may also affect the growth of the global weight loss and obesity management market adversely.

The global weight loss and obesity management market is estimated based on product type, and distribution sales. Based on product type, the weight loss and obesity management market has been segmented into drugs and devices.

Drugs product type segment is further segmented into GLP-1 receptor agonists, lipase inhibitors, serotonin receptor agonist, a combination drug, and others. Devices product type segment is further segmented into liposuction devices, bariatric stapling devices, gastric band, gastric balloon systems, gastric emptying systems, and gastric electrical stimulation systems.

Devices segment is expected to hold maximum market share in the global weight loss and obesity management market. Based on distribution sales, the weight loss and obesity management market has been segmented into institutional sales and retail sales. In terms of revenue, institutional sales dominated the global weight loss and obesity management market in 2017.

Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-411

Additional Questions Answered

Some of the additional questions addressed in this report on the weight loss and obesity management market-

  • What is the revenue potential of the weight loss and obesity management market across the regions of emerging economies?
  • Who are the key competitors in the weight loss and obesity management market and what are their portfolios?
  • What are the major challenges influencing the growth of the weight loss and obesity management market?

Segmentation

On the basis of product type

  • drugs
  • devices

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-411

On the basis of distribution sales

  • institutional sales
  • retail sales

On the basis of geographical

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)
  • emerging countries like China, Brazil, and India.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Smart Pill Boxes & Bottles Market is likely to reach a valuation of US$ 144.2 Million in 2022

Sales of smart pill boxes and bottles are likely to reach around 800 thousand in 2019. According to a new analytical research study by Future Market Insights (FMI), smart pill boxes and bottles market will remain a high growth-low volume landscape over the course of next few years. Over 43% of total sales will be accounted by smart pill boxes. The report envisages a higher rate of adoption for smart pill bottles.

Almost 70% of adult patients are observed to discontinue or manipulate drug therapy, resulting in non-adherence to prescribed medication. The study opines that this directly adds to the economic burden on healthcare delivery system in form of emergency cases and Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1710

Smart pill boxes and bottles are increasingly being perceived as a potential solution to such challenges posed by increased healthcare delivery costs. Significance of medication adherence continues to rise with increasing prevalence of chronic conditions, propelling demand for smart pill boxes and bottles.

Dementia and geriatric care remain the key application areas of smart pill boxes and bottles, according to the report. More than 80% of sales is accounted by aging patients and dementia-afflicted population. Cancer management is likely to emerge lucrative in terms of applicability in coming years.

With surging demand for high-quality healthcare delivery, senior care centers, hospitals, long-term care centers, and homecare settings are accelerating adoption of medication dispensers, thereby elevating the revenue growth of smart pill boxes and bottles market. Some of the leading companies are actively involved in the development of advanced technology medication dispensing devices with zero error risks during medication.

Home care settings maintain the highest consumption share in smart pill boxes and bottles market that roughly equates 65% of total sales. Almost a fifth of smart pill boxes and bottles sold are installed at seniors care and assisted living centers. FMI’s analysis indicates that long-term care centers are also creating promising market opportunities for smart pill boxes and bottles manufacturers and distributors.

North America continues to reign supreme owing to early adoption of advanced technology enabled smart pill boxes and bottles, accounting for more than a third of the global market revenue. European market for smart pill boxes and bottles also represents a substantial volume share, majorly driven by German patients. South and East Asian regions are briskly developing high-potential markets for manufacturers and distributors of smart pill boxes and bottles, says the report.

The vendor landscape of smart pill boxes and bottles market remains fairly consolidated and competitive, as Tier 1 manufacturers continue to account for a majority of share in the market in terms of volume. While dominance of Koninklijke Philips N.V., PharmRight Corporation & Livi, and AdhereTech prevails in smart pill boxes and bottles market, the report finds that the competition among these players is characterized by product innovation, new launches, and technological advancements.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-1710

Key Segment

By product type

Smart Pill Box

Smart Pill Bottles

By indication

dementia

Parkinson’s disease

cancer management

diabetes care

geriatric care

disability

others

By end user

Seniors Care & Assisted Living

Long Term Care Centers

Home Care Settings

By regions

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Connected Drug Delivery Devices Market is projected to reach US$ 1.6 Billion by 2028

[228 Pages Report] According to the analyst of Future Market Insights (FMI), the leading manufacturers of connected drug delivery devices are focusing collaboration with the software companies to assess the cloud data system in their devices.

The market for connected drug delivery devices is foreseen to witness a stellar growth rate of 25.6% from 2013 to 2028 rising to a valuation of US$ 1,304.7 Mn from US$ 132.2 Mn in 2022.

Moreover, it helps the manufacturer to launch the product more conveniently and to enhance their distribution channel. Manufacturers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.

The companies operating in the global connected drug delivery devices market are OPKO Health Inc., Bayer AG, 3M Company, West Pharmaceutical Services, Inc., and Teva Pharmaceutical Industries Ltd., among others.

Rapidly evolving technologies, for instance, cloud-based computing models, are enabling the healthcare industry towards a transition to a new architecture.

Cloud technology along with advances in mobility and telepresence solutions is expected to create new unwired business models capable of providing healthcare anywhere.

The use of cloud technology will increase, aided by the proliferation of mobile health applications to collect and send vital signs from wireless and wired remote patient and personal health monitoring devices. Cloud-based platforms and new IT service models will fundamentally change the healthcare business equations and create opportunities for new players to enter the industry.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2755

Growing Demand for Injectable Drug Delivery to Aid Market Growth

The rising preference for injectable drug delivery is anticipated to drive the market for sterile drugs globally. Self-administration of drugs through usage of pre-filled syringes is one of the ways that can help patients to save the fees given to a caregiver. There is an increased demand for large molecule drugs in pre-filled syringes as compared to small molecule drugs in pre-filled syringes

Following this opportunity, the manufacturers are expected to cash in on profits through introduction of smart injectable drug delivery mediums among their portfolio. The progress is expected to be more prominent in the allergic reactions (Anaphylaxis) indication segment. Further, an upsurge in the number of large molecule drugs that need to be manufactured in injectable format is expected to fuel the growth of the market. Likewise, data generated by bioavailability studies is proving to present a definitive relation between pharmacodynamics and pharmacokinetics for such sterile drugs, which is also expected to offer support to the growth of the market.

Mobile applications are also being used for the treatment of patients suffering from Alzheimer, Diabetes, COPD or Asthma. Mobile applications with the use of GPS help to track the patient location. If the patient is travelling away from the home, the caretaker can track the exact location of the patient and also track the consumption of dosage by using mobile application. Most of these applications have been developed for the cloud. Placing the wireless solution on a cloud storage system helps with connectivity issues and makes it easier to communicate across different information regimes.

Limited Knowledge and Adoption Rate among Patients to Hinder Growth Rate

The deployment of connected drug delivery devices is not yet widely promoted within the public health system. This is attributed to the high cost of the product, limited reimbursement, and dearth of awareness among the patients regarding the technology. Moreover, complexity and limited availability of the device further reduces penetration. For instance, interpretation of insulin delivery trend for analysis, is considered to be useful however, because of the complicated user interface, the patients cannot interpret them smoothly. As per the current scenario, such obstacles might directly have an adverse effect on the overall growth of the connected drug delivery devices market.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-2755

Key Segments of Connected Drug Delivery Devices Industry Survey Connected Drug Delivery Devices Market by Product Type:

  • Inhalation Devices
  • Injectable Devices
    • Handheld Injectable Devices
    • Wearable Injectable Devices

Connected Drug Delivery Devices Market by End User:

  • Hospitals
  • Clinics
  • Home Care

Connected Drug Delivery Devices Market by Application:

  • Anaphylaxis
  • Cardiovascular
  • Diabetes
  • Hormone Replacement
  • Others

Connected Drug Delivery Devices Market by Technology:

  • Bluetooth Drug Delivery Devices
  • Near Field Communication Drug Delivery Devices

Connected Drug Delivery Devices Market by Region:

  • North America Connected Drug Delivery Devices Market
  • Latin America Connected Drug Delivery Devices Market
  • Europe Connected Drug Delivery Devices Market
  • East Asia Connected Drug Delivery Devices Market
  • South Asia & Pacific Connected Drug Delivery Devices Market
  • Middle East & Africa (MEA) Connected Drug Delivery Devices Market

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Anaesthesia Machines Market is projected to be valued at US$ 2.4 Billion by 2028

Mergers and Collaborations to Present High Growth Opportunities for Market Players in the Coming Years

Mergers and collaborations between local and international players in developing regions are expected to present potential opportunities for growth in terms of successful market penetration and sales. The regional markets of Asia Pacific, Latin America and GCC countries is anticipated to create significant opportunities to players involved in anaesthesia machines market. This can be attributed to the increasing surgical procedures in these regions coupled with increasing per capita expenditure on cosmetic surgeries and other healthcare associated procedures. Players in this market are establishing business relationships with healthcare facilities in these regions as well as government agencies for long term gains and enhancing their presence in the region. Moreover, partnership programs between organizations and institutions are observed to facilitate anaesthesia training programs.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-789

The research report “Anaesthesia Machines Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” published by Future Market Insights throws light on several aspects driving the global market. The growth of the market is impacted by various trends, developments, drivers and challenges, the analysis of which is included in the fact based research report. The exhaustive research publication covers historical data analysis along with current scenario as well as future projections of the market from a value standpoint for a 10 year period, starting from 2017 till 2027. The analysis on various segments playing a major role in the expansion of the global anaesthesia market has been carried out to get a complete picture of the global market.

Increasing Need for Anaesthesia Procedures to Spur the Adoption of Anaesthesia Machines in the Coming Years

According to WHO (World Health Organization) and World Bank, by 2026, the treatments demanding surgeries and hence anaesthesia machines would eclipse that of tuberculosis and HIV as well as malaria. Current market scenario portrays the fact that about 30% of the population in the entire globe do not have access to surgeries. On the contrary, about 75% of major procedures are being performed in the wealthiest countries in the world whereas poor countries are witnessing only 3.5% of operations. Government bodies along with non-government institutions are continuously working on offering healthcare access to every region, which is expected to trigger the adoption of anaesthesia machines. The growing number of surgeries and increasing government support are expected to fuel the growth of the anaesthesia machines market at a global level in the years to follow.

Global Market for Anaesthesia Machines: Factors Promoting Growth

The global market for anaesthesia machines is influenced by several aspects that facilitate the growth of the global market. Few of these aspects include continual technological advancements in anaesthesia machines, integration of IT in healthcare systems pushing the demand for anaesthesia workstations, emergence of anaesthesia information management systems, increasing public and private investments in healthcare, expanding imports and exports of medical devices among different regions, expanding private sector, enhancement in product lines by various manufacturers of anaesthesia machines, growing trend of patient monitoring using IoT, favourable government support, increasing medical tourism, growing geriatric population and manufacturing of cost effective anaesthesia machines.

However, product recalls due to defects in devices, shortage of healthcare professionals, adoption of refurbished machines, lack of public access to healthcare facilities and lack of clinical resources are expected to pose hindrances to the growth of the global market.

Segmental Highlights on the Anaesthesia Machines Market

  • With respect to region, North America and Asia Pacific excluding Japan (APEJ) are expected to showcase high potential for growth. Anaesthesia machines market in North America (led by US) is estimated to be the largest, whereas the market in APEJ is expected to rise at a comparatively high value CAGR during the forecast period
  • With respect to modality, the standalone anaesthesia machines are expected to witness increased adoption across the globe in several hospitals and clinics. This segment is expected to lead the global market with a high valuation and projected to expand at a relatively high CAGR throughout the period of assessment

Top Players Competing in the Global Anaesthesia Machines Market

The research report includes profiles of major players operating in the anaesthesia machines market. To name a few, the report includes intelligence on players such as GE Healthcare, Drägerwerk AG & Co. KGaA, Mindray Medical International Limited, Getinge AB, Spacelabs Healthcare, Heyer Medical AG, Infinium Medical, Inc., ACOMA Medical Industry Co., Ltd., Chirana Medical A.S., DRE Medical, BPL Medical Technologies, Beijing Aeonmed Co. Ltd., Comen Medical Instruments Co. Ltd., Okuman Medical System Ltd., Narang Medical Limited and Lowenstein Medical GmbH & Co.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-789

Key Segments Covered

By Modality

  • Standalone Anaesthesia Machines
  • Portable Anaesthesia Machines

By End User

  • Hospitals
  • Surgical Ambulatory Centres
  • Clinics
  • Nursing Facilities

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Japan
  • Middle East and Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Cardiac Assist Devices Market is poised to expand at 5.29% CAGR, reaching US$ 2,062.7 Billion by 2031

Future Market Insight’s (FMI’s) latest study published on the Cardiac Assist Devices market provide insights into key factors uplifting the sales over the next ten years. It provides unbiased analysis on key trends, drivers, and opportunities across key segments, the report also provides strategic analysis on the incumbents, existing players, and leading players operating in the Cardiac Assist Devices market.As per comprehensive research conducted by ESOMAR-certified consulting firm FMI, the global Cardiac Assist Devices market is projected to witness robust growth during the forecast year 2021-2031. The report emphasizes on providing key insights into diverse features including demand, product developments, revenue generation, and sales in the Cardiac Assist Devices market.

Future Market Insights (FMI), a Leading Market Research and Competitive Intelligence Provider Offers Exhaustive Analysis on Key Factors Burgeoning the Sales in the Global Cardiac Assist Devices Market over the Assessment Period (2021-2031)

The study offers a detailed analysis of dynamics including driver, restraints, opportunities, and challenges, and also highlights their consequent impact on the market.

“To remain ‘ahead’ of your competitors, request for a sample”: https://www.futuremarketinsights.com/reports/sample/rep-gb-467

Advent of Telehealth and Virtual Care to Create Tailwind for the Cardiac Assist Devices Market Growth

Digitization is making deeper inroads across diverse industries, such as healthcare, owing to the increasing penetration of the internet and smartphones across the world.

During the COVID-19 outbreak, healthcare practitioners and patients realized the importance of digitization and encouraged them to adopt virtual methods of patient examination and consultation to counter the regulations concerning social distancing. This gave rise to a new medical domain, Telehealth.

Since the outbreak, telehealth have gained immense popularity, especially among the geriatric population, owing to the convenience associated with it. Hence, increasing adoption of telehealth across radiology, behavioral health, cardiology, and online consultation is expected to create lucrative opportunities for growth in the Cardiac Assist Devices market.

Key Cardiac Assist Devices Market Takeaways and Projections

The U.S. is estimated to continue dominating the North America market, projecting fastest growth in the region through 2031.
Germany Cardiac Assist Devices market is forecast to register robust growth in Europe, accounting for a significant share in the region between 2021 and 2031.
China is expected to account for the maximum revenue share in the East Asia market, exhibiting the fastest sales growth during the assessment period.
India is forecast to emerge as a highly remunerative market in South Asia, contributing for the largest sales in the region over the coming 10-years.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-467

Report Benefits & Key Questions Answered

Cardiac Assist Devices Historical Market Outlook: Future Market Insight’s analysis examines vital dynamics, such as drivers, opportunities, and challenges in the Cardiac Assist Devices market. It also studies the impact of these dynamics on the market for the previous assessment period 2016-2020 to forecast the scope of market growth over the coming forecast period 2021-2031.
Cardiac Assist Devices Demand-Supply Assessment: The latest study published by FMI offers in-depth insights into governing factors facilitating the demand outlook of the Cardiac Assist Devices market. As per the survey, Cardiac Assist Devices sales will project steady growth over the forecast period.

Cardiac Assist Devices Market Structure Analysis: The report provides detailed information about market the concentration of key players and tier analysis in the Cardiac Assist Devices market. It also categories market players as per Tier 1, Tier 2, and Tier 3 in terms of their percentage share and product portfolio.
Cardiac Assist Devices Category & Segment Level Analysis: FMI’s category & segment level analysis provides insights into key factors affecting the market growth across various segments in terms of (segment 1), (segment 2), and (segment 3). It also uncovers critical opportunities across each segment to assist key players to capitalize on the,
Cardiac Assist Devices Market Trend Analysis: FMI’s market trend analysis provide compelling insights into current and upcoming trends in the healthcare industries. It also assists the industry players to identify potential trends to formulate a strategy to take advantage of these existing trends.

For critical insights, request for PDF Brochure: @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-467

Competitive Landscape Analysis

The latest study conducted by FMI provides in-depth insights into the global Cardiac Assist Devices market to assist management level decision-makers in constructing a strategy to capitalize on the critical trends & opportunities. It also discloses competitive trends and profiles a list of leading players operating in the global Cardiac Assist Devices market.

Some of the prominent market players are profiled by FMI

Terumo Corporation
Medtronic PLC
Abbott Laboratories
Abiomed Inc.
Teleflex Incorporated
Maquet GmbH
BerlinHeart GmbH
Others

Cardiac Assist Devices Demand Analysis by Category
By Product Type:

Ventricular Assist Devices (VAD)
Left Ventricular Assist Device (LVAD)
Right Ventricular Assist Device (RVAD)
Biventricular Assist Device (BIVAD)
External Ventricular Assist Devices
Intra-Aortic Balloon Pump

By Modality Type:

Transcutaneous
Implantable

By End-User:

Hospital
Ambulatory Surgical Centers

Region

North America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Asthma and COPD Biomarkers Market to Witness Comprehensive Growth by 2028

Chronic Obstructive Pulmonary Disease (COPD) are a group of progressive lung diseases which interfere with the airflow and make it difficult to breathe. The lung disease include non-reversible asthma, emphysema chronic bronchitis. The air flow is narrowed due to the damage of the lung tissues.

Air pollution and smoking are the main risk factors of this disease. COPD is a common and incurable disease which is characterized by increased breathlessness, persistent respiratory symptoms and airflow limitations.

The biomarkers are obtained in the form of bronchi alveolar fluids sputum, blood, urine and exhaled breath. These compounds are produced by the metabolic process in the body and are non-invasive metabolic markers. These biomarkers provide information to verify the disease, its stage, treatment and responses.

Factor driving the Asthma and COPD Biomarker market

Asthma and COPD biomarker market is primarily driven by the increasing smoking rate and growing pollution levels. According to WHO reports 64 million people had COPD and 3 million people died of COPD in 2004.

Long-term exposure to chemical fumes, vapours and dusts are also some factors which are causing COPD and driving the market. Moreover the demand of breath analyzers is increasing in schools hospitals and other institutions to ensure the safety of the individuals.

The COPD biomarkers are non-invasive and are produced by the metabolic process in the body in the form of urine, sputum, and by exhaled breath etc.  Increased levels of FeNO (Fractional exhaled nitric oxide) in exhaled breath is obtained by the hand held breath analyzers.

These devices are easy to use and quick in diagnoses of the disease. Fibrinogen as a biomarker is measured in the plasma. Its increased levels provide the severity of COPD, airflow colonization and emphysema. The increased level of fibrinogen, white blood cells and C- reactive protein (CRP) combined together is accounted as a major risk for COPD. However, lack of awareness and diagnosis of chronic obstructive pulmonary diseases is hindering the growth of asthma and COPD biomarker market.

Also if the disease is not detected at the earliest stage it could lead to respiratory infections, heart problems, lung cancer and high blood pressure. The overall market of asthma and COPD biomarker is pushed by the increasing demand of growing expenditure on healthcare.

Asthma and COPD biomarker market offers the potential to identify disease in its earliest phase and the technology in the devices and the test kits holds a strong perception in future with its continued investment.

Request a Sample:

https://www.futuremarketinsights.com/reports/sample/rep-gb-6937

Regional Market Outlook

Geographically, asthma and COPD biomarker market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa and Japan.

The market in North America is expected to dominate the asthma and COPD biomarker market globally followed by Europe, North America is the dominant asthma and COPD biomarker market due incidences and prevalence of chronic pulmonary diseases in the region due to astringent and powerful regulations for the patient care and safety.

The market in Asia Pacific region is expected to grow at a higher rate with the awareness programs and with the increasing chronic obstructive pulmonary diseases in the population.

In addition, government initiatives on providing better healthcare facilities to the population contribute to the growth of the asthma and COPD biomarker market.  With the availability of new technologies in regions such as Asia Pacific and Latin America is going to further spur revenue growth during the forecast period.

Competition Outlook

Some of the major players identified in Asthma and COPD biomarker market are Spirosure inc. GE Healthcare, Astrazeneca, Owlstone Medical Ltd, Circassia Limited, Bedfont® Scientific Ltd., ECO MEDICS AG., Vitalograph, Mologic ltd,  Akers Biosciences, Inc  etc. The Companies are involved in collaboration agreements for R&D in order to exploit maximum potential. Also they are mainly focused to strengthen the core competencies of their product portfolio with the increasing demand for the diagnosis of COPD and asthma.

Research Methodology

The market sizing of Asthma and COPD biomarker market will be done by adoption data triangulation approach. Demand side approach will be followed to assess the actual market size of Asthma and COPD biomarker.

Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, equipment installed base in end use facilities, adoption rate and future impact of new technologies.

Additionally, per capita consumption of test and among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analyzed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side respondents such as physicians, laboratory and diagnostic laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and reagent manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-6937

Key data points covered in report

The report covers exhaustive analysis on:

  • Asthma and COPD biomarker market by target areas, modality, end user and region
  • Regional level market analysis of North America, Latin America, Europe, Asia Pacific, Middle East & Africa by method type, end user and country segments
  • Asthma and COPD biomarker Market Dynamics & Opportunity Assessment
  • Historical Actual Market Size, 2013 – 2017
  • Asthma and COPD biomarker market Size & Forecast 2018-2028
  • Asthma and COPD biomarker Current Trends/Issues/Challenges
  • Competition & Companies involved

Market Segmentation

Market by application

  • Chronic Bronchitis
  • Emphysema
  • Refractory Asthma

Market by Test Type

  • Breath Analyzing
  • Sputum tests
  • Urine tests
  • Plasma tests

Market by End user

  • Hospitals
  • Diagnostic Laboratories
  • Asthma Clinics

Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific Excluding Japan
  • Japan
  • Middle East & Africa

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-6937

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Direct-acting Antiviral Medicines Market Competitive Landscape, SWOT Analysis, Opportunities and Challenges, Growth 2028

Globally, the chronic hepatitis C virus (HCV) is the leading cause of liver diseases such as liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis C virus infection affects around 180 million people worldwide and in North America almost 3 million people were infected by hepatitis C virus, which further led towards liver transplantation.

Direct-acting antiviral medicines are widely used for the treatment of hepatitis C virus infection. HCV is a small positive-strand ribonucleic acid (RNA) virus in the Flaviviridae family. Specific non-structural protein of the hepatitis C virus are targeted by direct-acting antiviral molecules, which result in interruption of viral infection and replication. On the basis of mechanism and therapeutic target, direct-acting antiviral medicines are segmented into four classes.

The direct-acting antiviral medicines play a vital role to overcome the impact of hepatitis C virus infection by reducing the reoccurrence of the end-stage liver disease. The WHO also recommends direct-acting antiviral medicines for the treatment of life-threatening hepatitis C virus infection due to their efficacy and effective clearance of hepatitis C virus from the patient.

New Era of Direct-Acting Antiviral Drugs

The success rate for the treatment of chronic hepatitis C virus has improved significantly over the past several years due to the introduction of new direct-acting antiviral drugs, which have proven to be more effective than the conventional drugs. The conventional treatment of CHC is basically interferon-based interventions with serious side effects, but direct-acting antiviral drugs show relatively lower side effects, reduce the course of the therapy and also eradicate hepatitis C virus from the blood more much frequently.

The recently approved direct-acting antiviral drug, Epclusa tablet, is the combination of sofosbuvir and velpatasvir tablet that has capabilities to treat all the six major hepatitis C genotypes. Whereas, the mechanism of direct-acting antiviral drugs is based on interferon-free treatment.

Request a Sample:

https://www.futuremarketinsights.com/reports/sample/rep-gb-6605

Factors Driving Direct-acting Antiviral Medicines Market

The global market for direct-acting antiviral medicines is driven by increasing prevalence of liver cirrhosis and hepatocellular carcinoma and advancements in drug modification.

Most of the companies are involved in better availability of directly-acting antivirals medicines and strategic collaborations, which are also the driving factors for the direct-acting antiviral medicine market. Growing awareness and improving healthcare outlook in emerging countries have increased the demand for direct-acting antiviral medicine and act as the major driving factor for the direct-acting antiviral medicine market.

Factors Restraining Direct-acting Antiviral Medicines Market

Patent expiration of branded direct-acting antiviral is a prime challenge for the manufacturers, which leads to generic competition. Besides, side effects related to direct-acting antiviral medicines is the major restraints for the global direct-acting antiviral medicines market. In middle-income countries, costly, complex diagnostic and monitoring requirements also act as a barrier to HCV treatment and high cost of drugs can hamper the market growth.

Direct-acting Antiviral Medicines

Some of the commonly used direct-acting antiviral medicines for the treatment of chronic hepatitis C virus are Epclusa, Zepatier, Daklinza, Technivie , Viekira Pak, Harvoni, and Sovaldi, among others. A significant portion of the market has been covered by Epclusa, Sofosbuvir and Sovaldi due to their efficacy, reduced course time and low cost. They are used to treat hepatitis infected genotypes 1, 2, 3, 4, 5, and 6 with or without cirrhosis.

Moreover, approximately 75% of Americans with HCV have genotype 1, while 20–25% have genotypes 2 or 3.  While only a small number of people in the U.S. are infected with genotypes 4, 5, or 6, they remain the predominant strains in the Middle East, Southern Africa, and Asia. Promising revenue growth is considered for the direct-acting antiviral medicines market over the forecast period.

E-commerce Pharmacies Channel Shows Prominent Growth

Hospital pharmacies, drug stores, and retail pharmacies hold a strong position in the global direct-acting antiviral due to the easy availability of prescribed medicines. However, online pharmacies like e-commerce are also increasing the demand for drugs due to the more offers available on the online platform. Growing penetration of Direct-acting Antiviral on the online pharmacies will provide a remarkable growth opportunity for the manufacturers in underdeveloped economies. Further, the growing trend of online pharmacies would flourish the growth of Direct-acting Antiviral.

Regional Market Outlook

Based on geography, the global direct-acting antiviral medicines market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and the Middle East & Africa. North America followed by Europe will continue to dominate the global direct-acting antiviral medicines market in terms of revenue over the forecast period, owing to better reimbursement policy, high awareness and presence of the giant pharmaceutical key players in the region.

Furthermore, increasing prevalence of hepatitis C virus infection is higher in the region, which is expected to result in higher demand for direct-acting antiviral medicines over the forecast period. The Asia Pacific excluding Japan region shows significant growth due to the presence of a large number of hepatitis C virus infection cases, availability of direct-acting antiviral medicine in developing countries such as China and India is expected to boost the direct acting antiviral medicine market growth over the forecast period.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-6605

Competition Outlook

Examples of some of the key players in the global direct-acting antiviral medicines market are Gilead Sciences, Janssen Therapeutics, Division of Janssen Products, AbbVie., Bristol-Myers Squibb, Merck & Co., and Vertex Pharmaceuticals, among others. The major pharmaceutical companies are focusing on direct-acting antiviral drugs development, such as AbbVie is developing ABT-530 (an NS5A inhibitor) and ABT-493 (a protease inhibitor), Gilead’s FDC of sofosbuvir and GS-5816 (an NS5A inhibitor) is in phase III. Company-specific access strategies for low- and middle-income countries also create opportunities for the manufacturers.

  • Natco Pharma
  • Vertex Pharmaceuticals
  • Dr. Reddy’s Laboratories
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Gilead
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

 Key Data Points Covered in Report

  • Direct-acting antiviral medicines market by drug class, distribution channel, and region
  • Regional level market analysis of North America, Latin America, Western Europe, Eastern Europe, the Asia Pacific Excluding Japan, Japan, Middle East & Africa by drug class, distribution channel and country segments
  • Direct-acting antiviral medicines market dynamics & opportunity assessment
  • Historical actual market size, 2013 – 2017
  • Direct-acting antiviral medicines market size & forecast 2018-2028
  • Direct-acting antiviral medicines agents current trends/issues/challenges
  • Competition & companies involved

Research Methodology

The market sizing of direct-acting antiviral medicines will be done by experimental techniques such as patient-level data, to obtain precise market estimations and insights on molecule and drug classes, API formulations and preferred modes of administration. The demand-side approach will be followed to assess the actual market size of direct-acting antiviral medicines.

Secondary research will be used in the initial phase to identify the feasibility of the target drug categories and its respective segments, product and service offerings, adoption rate and future impact of new drugs. Additionally, per capita consumption of drugs, key treatment pattern, adoption rate and clinical application of drugs among end users are tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analyzed during the entire research project that builds a strong base for the primary research information.

Primary research participants include demand-side respondents such as, physicians, surgeons, nursing managers, clinical specialists, and key opinion leaders in addition to supply-side respondents, such as drug manufacturers and pharmacist, who provide valuable insights on trends, purchasing patterns, compliance rate and associated pricing.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-6605

Market Segmentation

By Drug Class

  • (NS3/4A) protease inhibitors
  • NS5B nucleoside polymerase inhibitors
  • NS5B non-nucleoside polymerase inhibitors
  • NS5A inhibitors

By Distribution Channel

  • Retail Pharmacies
  • Hospitals pharmacies
  • Drug-store
  • Online\e-commerce
  • Others

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Hirschsprung Disease Treatment Market Demands, Regional Developments and Industry Competitive Landscape Analysis 2027

Hirschsprung disease is a condition in which certain nerve fibers are absent in the segment of the bowel results in partial or full blockage of a stool which further leads to severe infection and damage to the colon. The condition is present at the newborn period and later in infancy and childhood as a result of missing nerve cells in the muscles of the baby’s colon, and children are prone to a severe intestinal infection called enterocolitis which can be a life threatening.

Mortality from enterocolitis or surgical complications in infancy is 25-30%. Hirschsprung disease is a common cause of chronic constipation. Hirschsprung’s disease is associated with certain inherited conditions, such as Down syndrome and other abnormalities present at birth, such as congenital heart disease.

Hirschsprung’s disease occurs once in every 5,000 live births and is about four times more common in males than females.Hirschsprung disease affects all races; however, it is roughly three times more common among Asian-Americans.  The main signs and symptoms of Hirschsprung disease are constipation or intestinal obstruction, usually appearing shortly after birth.

Most often, an infant or a child with Hirschsprung disease will have other symptoms, including growth failure, swelling of the abdomen, unexplained fever, or vomiting. However, Hirschsprung disease can be treated, depending on the bowel condition and its severity and based on the patient’s symptoms and medical history; this is expected to reflect positive growth in the global Hirschsprung disease treatmentmarket.

Hirschsprung Disease Treatment Market: Drivers and Restraints

Technology advancements in healthcare related to research and development of new therapies and drugs are now curing life-threatening diseases and giving promising results. Increasing the prevalence rate of such diseases with increasing number of diagnosed infants with Hirschsprung Disease across the globe are driving the Hirschsprung Disease Treatment market.

However, some of the restraints also are there that hamper the Hirschsprung Disease Treatmentmarket growth such factor are the lack of definitive treatment options & misdiagnosis of the diseaseand limited access to healthcare services in various countries.

Request a Sample:

https://www.futuremarketinsights.com/reports/sample/rep-gb-5049

Hirschsprung Disease Treatment Market: Overview

Continuous investment by government in clinical research to get the new ways to prevent, detect, or treat disease. Researchers also use clinical trials to look at other aspects of care, such as improving the quality of life for people with chronic illnesses.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and other components of the National Institutes of Health (NIH) conduct and support research into such diseases and conditions. This is expected to drive the growth of Hirschsprung Disease Treatmentmarket during the forecast period.

Prognosis of Hirschsprung Disease with the help of diagnostic tests at regular intervals is also expected to propel the Hirschsprung Disease Treatment market.

Hirschsprung Disease Treatment Market: Region-wise Outlook

Based on geography, Hirschsprung Disease Treatment market has been segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, and Middle East & Africa. North America is relied upon to represent tremendous commitment under Hirschsprung Disease Treatment by income era due to well-developed diagnosis and treatment centers with affordability to health care facilities.

Stimulated advancement in old technology and increasing awareness about disorders through government in Europe exhibits the rise of the Hirschsprung Disease Treatmentmarket. China, India are also relied upon to show high development rate, because of increases in research centers and adoption of these procedures in clinical practice with improved clinical outcomes that would push the Hirschsprung Disease Treatment market growth.

Hirschsprung Disease Treatment Market: Key Market Participants

Some of the major key players of Hirschsprung Disease Treatment market constitute: Pfizer, Sanofi, Bayer Healthcare, Johnson and Johnson Merck & Co., Novartis AG, Bristol-Myers Squibb, Astellas Pharma, Inc., Eli Lilly and Company, Abbott, Panacea Biotech Ltd. Cipla Ltd., GlaxoSmithKline  Dr. Reddy’s Laboratories Ltd,  and Baxter International.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-5049

The report covers exhaustive analysis on

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

The regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-5049

Hirschsprung Disease Treatment Market: Segmentation

The global market for Hirschsprung Disease Treatment is segmented on the basis of Drug Class, Distribution Channel, and geography:

Based on Drug Class, Hirschsprung Disease Treatment market is segmented into the following:

  • Anti-infective
  • Analgesics
  • Antiemetic

Based on Distribution Channel, Hirschsprung Disease Treatment market is segmented into the following:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Mail Order Pharmacies

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Infusion Pharmacy Management Market Production, Growth, Share, Demand and Applications Forecast to 2027

Infusion therapy is type of medication through a needle or catheter. Infusion therapy is prescribed to patient only when patient condition is severe or oral medication are less effective. Infusion Pharmacy include infusion of antibiotic, antifungal, antiviral, pain management and nutritional drug through needle or catheter. Diseases such as cancer, diabetes, gastrointestinal disorder and pain related disorders are generally treated with infusion medication system.

Infusion pharmacy can also be administered in home by providing doorstep services. Home infusion pharmacy management is more costly than hospital infusion pharmacy management because it require more skilled nursing facilities. Infusion pharmacy management are covered with government as well as private insurance plan

Infusion Pharmacy Management Market: Drivers and Restraints

Increasing prevalence of pain, cancer and diabetes is the primary factor driving the growth of infusion pharmacy management market. Increasing healthcare infrastructure and technological advancement by leading pharmaceutical companies will boost the growth of infusion pharmacy management market. Infusion medication is more efficient than oral medication which will again upsurge the growth of infusion pharmacy management market.

The high cost of infusion pharmacy and lack of availability of skilled professional will hinder the growth of infusion pharmacy management market. Beside that risk in patient safety leads to less adoption of infusion pharmacy will restrain the growth of this market.

Request a Sample:

https://www.futuremarketinsights.com/reports/sample/rep-gb-4291

Infusion Pharmacy Management Market: Overview

The infusion pharmacy management market is expected to show robust growth over the forecast period due to rising incidences of chronic diseases. Infusion pharmacy management market is completely depend on the nurses. The nurse proving regular infusion medication to patient needs to be finely trained. The infusion pharmacy management is segmented on the basis of services and end user.

By service type, infusion pharmacy management market is classified as total parenteral nutrition, antibiotics, antifungal, anti-nutrition, pain management. Pain management infusion pharmacy is expected to show fastest growth over the forecast period.

Based on end user infusion pharmacy management market is classified as hospital, ambulatory surgical centres, specialty clinics, and homecare settings. Among all end user the hospital segment is expected to be most lucrative over the forecast period.

Infusion Pharmacy Management Market: Regional Overview

Based on geographic region Infusion Pharmacy Management market is classified into seven key regions, North, America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa. North America is expected to dominate the infusion pharmacy management market over the forecast period owing to high healthcare infrastructure. After North America, infusion pharmacy management market dominated by Western Europe.

Increasing pharmacy management companies in Germany and U.K. will upsurge the growth of infusion pharmacy management market in Europe. In APEJ region, India and China are the major market for infusion pharmacy management due increasing geriatric population Middle East & Africa and Latin America are expected to show least growth for infusion pharmacy management market over the forecast period.

Infusion Pharmacy Management Market: Key Players

Examples of some of the market participants in Infusion Pharmacy Management market identified across the value chain include Managed Health Care Associates, Inc., Southside Group of Companies, ContinuumRx, Cigna, ARJ Infusion Services, CareCentrix, Inc., MedicoRx.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-4291

The report covers exhaust analysis on

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

The regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-4291

Infusion Pharmacy Management Market: Segmentation

The global infusion pharmacy management market is classified on the basis of service, end user and geographic region.

Based on service, infusion pharmacy management market is segmented into following:

  • Total Parenteral Nutrition
  • Antibiotics
  • Antifungal
  • Anti-nutrition
  • Pain management
  • Others

Based on end user, infusion pharmacy management market is segmented into following:

  • Hospital
  • Ambulatory Surgical Centers
  • Specialty Clincs
  • Homecare Setting

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Carcinoid Syndrome Diarrhea Treatment Market Size, Share, Growth, Trends, Industry Analysis | 2027

Carcinoid syndrome is associated with carcinoid tumor and is classified as rare cancerous tumor cells secreting chemicals into the bloodstream affecting gastrointestinal tract or lungs. In the advanced-stage carcinoid tumors might affect by causing heart diseases, diarrhea, and carcinoid crisis. If carcinoid tumor is not detected, carcinoid syndrome can be undiagnosed as its symptoms resemble other diseases such as asthma, irritable bowel disease, and menopause

Carcinoid Syndrome Diarrhea Treatment Market: Overview

Carcinoid syndrome diarrhea is characterized by symptoms such as facial flushing, abdominal discomfort, fatigue, and may lead damage in the heart valve. The patients of carcinoid syndrome release a high amount of serotonin which leads to uncontrolled diarrhea. If carcinoid syndrome diarrhea is not treated it may lead to excessive weight loss, dehydration, electrolyte imbalance, and other life-threatening symptoms.

Carcinoid Syndrome Diarrhea Treatment Market: Drivers and Restraints

Carcinoid syndrome diarrhea treatment market would grow during the forecast years as many multi-national companies are focusing towards new product innovations in carcinoid syndrome diarrhea treatment.

Also, the market for carcinoid syndrome diarrhea treatment would experience a boost as the treatment available for this disease are limited, and the company’s manufacturing drugs would target a wide market hence gaining huge market share in the carcinoid syndrome diarrhea treatment market.

According to American Cancer Society, the worldwide incidence of carcinoid tumor is estimated that approximately 8000 adults in the United States are diagnosed with a carcinoid tumor in the gastrointestinal tract.

Other factors contributing to carcinoid syndrome diarrhea treatment market are increasing the incidence of hormonal disorders, growing smoking habits, and increasing prevalence of the disease. The market for carcinoid syndrome diarrhea treatment would be affected due to the low availability of therapeutic options for treatment of the disease.

Request a Sample:

https://www.futuremarketinsights.com/reports/sample/rep-gb-3999

Carcinoid Syndrome Diarrhea Treatment Market: Region Wise Outlook

Geographically, the Carcinoid Syndrome Diarrhea Treatment market can be segmented into seven regions, North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is the most attractive region for the carcinoid syndrome diarrhea treatment market attributing to the increasing prevalence of the disease in this region.

Followed by which is Europe and Japan as the leading regions in carcinoid syndrome diarrhea treatment market. These markets are also growing significantly due to the focus on the new therapy developments for carcinoid syndrome diarrhea treatment which would ease in the reduction of incidence rare.

Asia Pacific excluding Japan is also expected to show significant growth in carcinoid syndrome diarrhea treatment market due to increase in research and development activities, and development of healthcare infrastructure in this region. Asia-Pacific excluding Japan region has the presence of many small players which are operating at a regional level and contribute to a significant market share of the carcinoid syndrome diarrhea treatment market.

Carcinoid Syndrome Diarrhea Treatment Market: Key Players

The major participants in the global carcinoid syndrome diarrhea treatment market are Lexicon Pharmaceuticals, Inc., Novartis International AG (Sandoz), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Biopharmaceuticals, Inc., Sirtex Medical Limited, BTG International Ltd among others.

Lexicon Pharmaceuticals, Inc.is the first company to gain approval by U.S. Food and Drug Administration for orally administered therapy drug for the treatment of carcinoid syndrome diarrhea. As the treatment available for carcinoid syndrome diarrhea are limited, multiple companies are focusing on increased research and development for new targeted delivery of disease and targeting huge market share.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and grades.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-3999

The report covers exhaustive analysis on

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2012 – 2016
  • Market Size & Forecast 2017 to 2027
  • Supply & Demand Value Chain
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis for Market includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific & Japan
  • The Middle East and Africa

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-3999

Carcinoid Syndrome Diarrhea Treatment Market: Segmentation

The market for Carcinoid Syndrome Diarrhea Treatment can be primarily segmented into the various therapy types, distribution channel, and regions:

By Therapy Types:

  • Chemotherapy
  • Somatostatin Analog (SSA) Therapy
  • Oral Therapy

By Distribution Channels:

  • Speciality Pharmacy
  • Retail Pharmacy
  • Prescription Drug Stores
  • Mail Order Pharmacy

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs